English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis
English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis
复制标题
DOI：
10.1111/1346-8138.16635
复制
发表时间：
2022-11-22
影响因子：
3.1
通讯作者：
Ohtsuki, Mamitaro
中科院分区：
文献类型：
--
作者：
Saeki, Hidehisa;Akiyama, Masashi;Ohtsuki, Mamitaro
这是使用口服Janus激酶（JAK）抑制剂治疗特应性皮炎指南的英文版。几种细胞因子，如白细胞介素（IL）-4，IL-13，IL-22，IL-31，胸腺基质淋巴细胞生成素和干扰素-γ，参与特应性皮炎的发病机制。由于口服JAK抑制剂阻碍JAK信号转导子和转录信号转导途径的激活子参与这些细胞因子的信号转导，因此它们可有效治疗特应性皮炎。在日本，作为特应性皮炎的口服JAK抑制剂，JAK 1/2抑制剂baricitinib于2020年扩大了特应性皮炎的授权适应症。因此，JAK 1抑制剂upadacitinib亦于2021年将其适应症扩展至特应性皮炎，随后另一种JAK 1抑制剂abrocitinib获新批准在日本医疗保险制度下使用。打算使用这些药物的医生应充分了解并遵守日本厚生劳动省制定的指南内容，以促进这些药物的最佳使用。在口服JAK抑制剂治疗中，应充分考虑疾病因素、治疗因素和患者背景，并与患者分享以选择治疗方案。药物选择的考虑因素包括药物的疗效和安全性、患者年龄以及药物的剂量和用法。本指南是为委员会认证的皮肤科医生开发的，他们专门从事特应性皮炎的治疗，并促进正确使用口服JAK抑制剂，同时考虑到个体患者的各种因素。
This is the English version of guidance for the use of oral Janus kinase (JAK) inhibitors in the treatment of atopic dermatitis. Several cytokines, such as interleukin (IL)-4, IL-13, IL-22, IL-31, thymic stromal lymphopoietin, and interferon-gamma, are involved in the pathogenesis of atopic dermatitis. As oral JAK inhibitors hinder the JAK-signal transducers and activators of transcription signal transduction routes involved in the signal transduction of these cytokines, they may be effective for the treatment of atopic dermatitis. In Japan, as oral JAK inhibitors for atopic dermatitis, a JAK1/2 inhibitor, baricitinib, expanded its authorized indications for atopic dermatitis in 2020. Consequentially, a JAK1 inhibitor, upadacitinib, also expanded its indications to atopic dermatitis in 2021, followed by new approval of another JAK1 inhibitor, abrocitinib, for the use under the Japanese health insurance system. Physicians who intend to use them should sufficiently understand and comply with contents of guidelines prepared by the Japanese Ministry of Health, Labour and Welfare to promote optimal use of these drugs. In the treatment with oral JAK inhibitors, it is important to sufficiently consider disease factors, treatment factors and patient backgrounds, and share them with patients to choose treatment options. Points to be considered for drug selection include the efficacy and safety of drugs, age of patients, and dosage and administration of the drug. This guidance was developed for board certified dermatologists, who are specialized in the treatment of atopic dermatitis, and for promoting proper use of oral JAK inhibitors, taking into account a variety of factors in individual patients.